Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effective and safe examination of Luseogliflozin for patients with fatty liver merger type II diabetes mellitus

Next Previous
X
Search
Trial Profile

Effective and safe examination of Luseogliflozin for patients with fatty liver merger type II diabetes mellitus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Luseogliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms LEAD

    • Most Recent Events

    • 01 Jan 2019 Primary endpoint (Rate of change of fat ratio in the liver) has been met as per results published in the Hepatology Research
    • 01 Jan 2019 Primary endpoint (Change in HbA1c) has been met as per results published in the Hepatology Research
    • 01 Jan 2019 Results published in the Hepatology Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top